Key result
Intravenous bivalirudin was well tolerated in healthy Chinese subjects, exhibiting a short half-life of approximately 0.57 hours and predictable, dose-dependent anticoagulant effects.
Why the study?
What are the pharmacokinetics, pharmacodynamics, and safety of intravenous bivalirudin in healthy Chinese subjects?
RCT (n=48)
Single-blind
Computerized random numbers
No
What are the pharmacokinetics, pharmacodynamics, and safety of intravenous bivalirudin in healthy Chinese subjects?
Bivalirudin exhibits similar pharmacokinetics and pharmacodynamics in healthy Chinese subjects as in Caucasian patients, suggesting the same dosing regimens can be used.
No takes yet. Share an insight, caveat, or question.
Supports standard bivalirudin dosing in Chinese patients; confirms similar PK/PD to Caucasian data.
Zhang et al. (2011) conducted an RCT in Healthy subjects (n=48). Bivalirudin vs. Placebo was evaluated on Pharmacokinetics (half-life, AUC, Cmax) and Pharmacodynamics (ACT, APTT, PT). Intravenous bivalirudin was well tolerated in healthy Chinese subjects, exhibiting a short half-life of approximately 0.57 hours and predictable, dose-dependent anticoagulant effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: